-40.7%
OKLO vs MRNA
+511.3%
-552.0%
-78.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.6% | -2.2% | +5.8% | +3.8% |
| 7D | +2.8% | +5.5% | -2.7% | +2.3% |
| 30D | -4.0% | +158.7% | -162.7% | -18.4% |
| 3M | -36.9% | +182.1% | -219.0% | -48.4% |
| 6M | -37.1% | +151.8% | -189.0% | -47.2% |
| YTD | -42.5% | +393.6% | -436.0% | -60.0% |
| 1Y | -40.7% | +499.5% | -540.2% | -60.1% |
| All | -40.7% | +511.3% | -552.0% | -60.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling